Efficacy of nirsevimab for the prevention of RSV disease in infants: A systematic review, meta-analysis of randomized controlled trials, and global perspectives on recommendations and unmet needs

Background: Respiratory syncytial virus (RSV) is a major cause of infant hospitalizations, with limited prophylactic options historically available. Nirsevimab, a long-acting monoclonal antibody, has emerged as a promising agent for preventing RSV. Objective: To evaluate the efficacy and safety of n...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Hsin-Chweng Lien, Chi-Hone Lien, Tzu-Yu Liu, Shun-Long Weng, Yu-Lin Tai, Ya-Ning Huang, Hsin Chi, Nan-Chang Chiu, Chun-Yan Yeung, Chien-Yu Lin
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2026-05-01
Serija:	Pediatrics and Neonatology
Teme:	Nirsevimab Respiratory syncytial virus RSV Monoclonal antibody Passive immunity Beyfortus
Online dostop:	http://www.sciencedirect.com/science/article/pii/S1875957225002001
Oznake:	Označite Brez oznak, prvi označite!